We are investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Vesper Healthcare Acquisition Corp. (“Vesper” or the “Company”) (NASDAQ:VSPR) in connection with the Company’s proposed merger with The HydraFacial Company (“HydraFacial”), a privately-held category-creating beauty health company.  Under the terms of the merger agreement, Vesper will acquire HydraFacial through a reverse merger that will result in HydraFacial becoming a public company traded on the NASDAQ exchange.  The transaction values HydraFacial at an enterprise value of approximately $1.1 billion.

WeissLaw is investigating whether Vesper’s board acted in the best interest of Vesper’s public shareholders in agreeing to the proposed transaction, whether the board was fully informed as to the valuation of HydraFacial, and whether all information regarding the process undertaken by the board and the valuation of the transaction will be fully and fairly disclosed to Vesper public shareholders.\n\nWeissLaw LLP has litigated hundreds of stockholder class and derivative actions for violations of corporate and fiduciary duties.  We have recovered over a billion dollars for defrauded clients and obtained important corporate governance relief in many of these cases.  If you have information or would like legal advice concerning possible corporate wrongdoing (including insider trading, waste of corporate assets, accounting fraud, or materially misleading information), consumer fraud (including false advertising, defective products, or other deceptive business practices), or anti-trust violations, please email us at stockinfo@weisslawllp.com